Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 31-34

  Bokemeyer, C ^a   Beyer, J ^b   Metzner, B ^c   Ruther U ^d   Harstrick, A ^e   Weissbach L ^f   Kohrmann U ^g   Verbeek, W ^h   Schmoll, H J ⁱ  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c KLINIKUM OLDENBURG   (Germany)

^d KATHARINENHOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f VIVANTES KLINIKUM AM URBAN   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Chemotherapy; Cisplatin resistance; Paclitaxel; Phase II study; Testicular cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MULTICENTER STUDY; NEUROPATHY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TESTIS CANCER;

EID: 0030052587     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010473     Document Type: Article

References (18)

1. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 8: 1777-81.
2. Harstrick A, Schmoll HJ, Wilke H et al. High-dose epidoxorubicin in refractory or relapsed nonseminomatous testicular cancer: A phase II study. Ann Oncol 1990; 375-6.
3. Bokemeyer C, Droz JP, Hanauske A et al. Treatment of relapsed germ cell tumors with vinorelbine: A trial of the phase I/II-study group of the association for medical oncology of the German cancer society. Onkologie 1993; 16: 29-31.
4. McGuire WP, Rowinsky EK. Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
5. Kohn EC, Sarosy G, Bicher A et al. Dose-intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
6. Reichman BS, Seidman AD, Crown JP et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 83: 1797-805.
7. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 655-67.
8. Brown T, Havlin K, Weiss G et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261-7.
9. Kris MG, O'Connell JP, Gralla RJ et al. Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 1986; 70: 605-7.
10. Bokemeyer C, Schmoll HJ, Natt F et al. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 1994; 120: 754-7.
11. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83.
12. Motzer RJ, Chou TC, Schwartz LH et al. Paclitaxel in germ cell cancer. Semin Oncol 1995; 22 (Suppl 6): 12-5.
13. Chou TC, Motzer RJ, Tong Y et al. Computerized quantitation of synergy of various drugs against teratocarcinoma cells in vitro: A rational approach to clinical protocol design. Proc Am Assoc Center Res 1994; 35: 254 (Abstr 1520).
14. Reed E, Parker RJ, Dabholkar M. Taxol effect on cisplatin-DNA adduct repair in human ovarian cancer cells. Second National Cancer Institute Workshop on Taxol, Alexandria, VA (Abstr) 1992.
15. Chao CCK, Lee YL, Cheng PW et al. Enhanced host cell reactivation of damaged plasmid DNA in HeLA cells resistant to cis-diamminedichloroplatinum (II). Cancer Res 1991; 51: 601-5.
16. Hill BT, Shellard SA, Whelan RDH et al. Deficient removal of the major platinum-DNA intrastrand crosslinks in the sequences pGpG and pApG appears characteristic of testicular teratoma cell lines derived from tumours from untreated patients and may account for their sensitivity to cisplatin. Proc Am Soc Oncol 1992; 11: 100 (Abstr 221).
17. Reed E, Kohn EC, Sarosy G et al. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: Molecular rationale and early clinical results. Semin Oncol 1995; 22 (Suppl 6): 90-6.
18. Forastiere AA, Susan GU. Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995; 22 (Suppl 6): 24-7.